Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Revenue projections:

Revenue projections for TORNTPHARM
Revenue projections for TORNTPHARM

TORNTPHARM's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 0.00000
forwardPE 63.92374
debtToEquity 33.40000
earningsGrowth 0.26100
revenueGrowth 0.17600
grossMargins 0.75641
operatingMargins 0.26703
trailingEps 67.11000
forwardEps 64.40800

Torrent Pharmaceuticals Limited's high forward PE indicates potential overvaluation, which may restrict future price increases and prompt a correction. Investors should evaluate this metric carefully in conjunction with other fundamental indicators to assess the stock's true growth potential.
TORNTPHARM's positive earnings and revenue growth reflect an optimistic outlook for the company's future. The growth in these key areas indicates that TORNTPHARM is expected to continue expanding its business and boosting its financial performance in the coming periods.
TORNTPHARM's positive gross and operating margins reflect strong financial performance. These metrics indicate that the company is efficiently managing its operations and generating healthy profits, contributing to a solid financial position.
Torrent Pharmaceuticals Limited's forward EPS, being lower than its trailing EPS, points to an expected decline in profitability. This suggests that the company's financial performance may weaken in the upcoming year.

Price projections:

Price projections for TORNTPHARM
Price projections for TORNTPHARM

TORNTPHARM's price projections have gradually increased over time, indicating that analysts are becoming more optimistic about the company's prospects. This suggests confidence in TORNTPHARM's ability to achieve future growth.

Recommendation changes over time:

Recommendations trend for TORNTPHARM
Recommendations trend for TORNTPHARM


Analysts' recent buy bias toward TORNTPHARM suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see TORNTPHARM as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.